[Killing activity of cytotoxic T lymphocytes stimulated by dendritic cell vaccine loaded with autologous cervical cancer antigen].
OBJECTIVE
Dendritic cells (DCs), the strongest antigen-presenting cells (APCs), can present antigens to T lymphocytes in vivo and in vitro, and induce cytotoxic T lymphocyte (CTL) reaction. This study was designed to investigate the killing activity of CTLs stimulated by Dcs loaded with autologous cervical cancer antigen in vitro.


METHODS
Tumor antigens were made from frozen-thawed cervical cancer cells from patients after operation. DCs were isolated from peripheral blood mononuclear cells of patients with cervical cancer, cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4), loaded with tumor antigen to prepare DC vaccine, and used to stimulate autologous T lymphocytes to prepare antigen-specific CTLs. The killing activities of CTLs on autologous cervical cancer cells and HeLa, HepG2, MCF7, A549, and MGC803 cells were observed.


RESULTS
CTLs stimulated by the DC vaccine had high killing activity on autologous cervical cancer cells, with killing rates of 79.32%-89.27% which were obviously higher than that of lymphokine-activated killing cells (t> or =2.89, P<0.05). The killing activity of CTLs was significantly weaker on HeLa cells (40.35%-58.09%) than on autologous cervical cancer cells (t> or =2.97, P<0.05). The specific CTLs had no obvious killing activity on HepG2, MCF7, A549, and MGC803 cells.


CONCLUSIONS
CTLs stimulated by autologous cervical cancer antigen-loaded DCs have highly efficient and specific immune activity on autologous cervical cancer cells. It may be used in biotherapy for cervical cancer.
Department of Obstetrics and Gynecology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P. R. China. 8808816@163.com
Chang-Ju
CJ
Zhou
Wei
W
Ma
Jian-Da
JD
Zhou
Yong-Xiang
YX
Zhao
Hui-Qing
HQ
Xie
D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000473:pathology; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D006801:Humans; D015847:Interleukin-4 / Q000494:pharmacology; D008213:Lymphocyte Activation; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000473:pathology
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D015847:Interleukin-4; D016178:Granulocyte-Macrophage Colony-Stimulating Factor